Danish pharmaceutical company Novo Nordisk (NYSE: NVO) is pioneering a new wave of medical treatment for diabetes and obesity ...

Discover the latest research on Ozempic and other GLP-1 medications, including potential uses in treating Alzheimer's and opioid and alcohol use disorders.

DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing blood sugar groups KELOWNA, BC / ...

THEY are the drugs that have taken 2024 by storm – and now weight loss injections could come with yet more added benefits. So-called skinny jabs – that were initially designed as ...

The joint venture with PlantX will provide LIV3 with the resources to create a strong online presence for SugarShield. PlantX's expertise in branding and digital platforms will help the supplement ...

The full-year cost of care for U.S. patients with obesity two years after starting on Novo Nordisk’s Wegovy or similar GLP-1 ...

Lexaria Bioscience (LEXX) has released an update. Lexaria Bioscience has reported promising results from its diabetes animal study, revealing ...

Lexaria Bioscience Corp., a global innovator in drug delivery platforms announced that dosing has begun, for human pilot study #3, investigating a DehydraTECH-processed version of the dual action ...

Lexaria Bioscience (LEXX) received partial 12-week blood sugar results from the recently completed animal study WEIGHT-A24-1. The company said, ...

Yet another therapy with FDA accelerated approval suffers a setback; Sage’s tough year continues; Sanofi drops $326 million ...

On October 21, Novo Nordisk announced positive news on the cardiovascular benefits of its oral glucagon-like peptide-1 ...

In announcing the results, Novo Nordisk said Rybelsus, an oral glucagon-like peptide-1 (GLP-1) receptor agonist already ...